Inovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in Stock

Inovio Pharmaceuticals Inc (NASDAQ:INO) Director Simon X. Benito sold 3,750 shares of the stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $5.23, for a total transaction of $19,612.50. Following the transaction, the director now directly owns 31,548 shares in the company, valued at approximately $164,996.04. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Inovio Pharmaceuticals stock traded down $0.10 during trading hours on Friday, reaching $5.06. The stock had a trading volume of 868,577 shares, compared to its average volume of 1,328,305. The firm has a market cap of $444.43, a PE ratio of -4.64 and a beta of 2.51. Inovio Pharmaceuticals Inc has a 52 week low of $3.76 and a 52 week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06. The business had revenue of $8.80 million for the quarter, compared to analyst estimates of $9.13 million. Inovio Pharmaceuticals had a negative net margin of 208.92% and a negative return on equity of 66.07%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.35) EPS. sell-side analysts expect that Inovio Pharmaceuticals Inc will post -1.07 earnings per share for the current year.



A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of Inovio Pharmaceuticals by 10.5% in the 4th quarter. Geode Capital Management LLC now owns 833,627 shares of the biopharmaceutical company’s stock worth $3,442,000 after purchasing an additional 79,001 shares during the period. Deutsche Bank AG lifted its position in shares of Inovio Pharmaceuticals by 247.7% in the 4th quarter. Deutsche Bank AG now owns 449,708 shares of the biopharmaceutical company’s stock worth $1,856,000 after purchasing an additional 320,376 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Inovio Pharmaceuticals by 17.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 382,206 shares of the biopharmaceutical company’s stock worth $2,423,000 after purchasing an additional 56,623 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth about $1,503,000. Finally, Vident Investment Advisory LLC lifted its position in shares of Inovio Pharmaceuticals by 95.3% in the 4th quarter. Vident Investment Advisory LLC now owns 291,713 shares of the biopharmaceutical company’s stock worth $1,205,000 after purchasing an additional 142,328 shares during the period. 31.50% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently commented on INO. BidaskClub raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, March 21st. Maxim Group set a $8.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Finally, Royal Bank of Canada increased their target price on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, March 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $19.07.

TRADEMARK VIOLATION NOTICE: “Inovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in Stock” was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://dakotafinancialnews.com/2018/04/13/inovio-pharmaceuticals-inc-ino-director-sells-19612-50-in-stock.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply